Locoregional Therapy for Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 395-421

  Guimaraes, Marcelo ^a   Uflacker, Renan ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Chemoembolization; Hepatocellular carcinoma; Liver tumor ablation; Locoregional therapy; Radioembolization; TACE

Indexed keywords

ALPHA FETOPROTEIN; ANTIBIOTIC AGENT; BILIRUBIN; CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; IODINATED POPPYSEED OIL; MITOMYCIN C; SORAFENIB; VASCULOTROPIN; YTTRIUM 90;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANOREXIA; BILIRUBIN BLOOD LEVEL; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOEMBOLIZATION; CHILD TURCOTTE PUGH; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIARRHEA; DRUG WITHDRAWAL; ELECTROPORATION; EXTERNAL BEAM RADIOTHERAPY; FEVER; GALLBLADDER DISEASE; HAIR LOSS; HEPATITIS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; INTESTINE INJURY; LASER SURGERY; LEUKOCYTOSIS; LIVER ABSCESS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FUNCTION; LIVER HEMORRHAGE; LIVER RESECTION; LIVER TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; META ANALYSIS (TOPIC); MICROWAVE THERAPY; MODEL FOR END STAGE LIVER DISEASE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARTIAL HEPATECTOMY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ABLATION TECHNIQUES; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; HUMANS; HYPERTHERMIA, INDUCED; LIVER NEOPLASMS;

EID: 79959321485     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.013     Document Type: Review

References (118)

1. Said A., Wells J. Management of hepatocellular carcinoma. Minerva Med 2009, 100:51-68.
2. Stravitz R.T., Heuman D.M., Chand N., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008, 121:119-126.
3. Pawlik T.M., Delman K.A., Vauthey J.N., et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005, 11:1086-1092.
4. Otto G., Heuschen U., Hofmann W.J., et al. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg 1998, 227:424-432.
5. Poon R.T., Fan S.T., Lo C.M., et al. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002, 235:373-382.
6. Jonas S., Bechstein W.O., Steinmüller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086.
7. Figueras J., Jaurrieta E., Valls C., et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology 1997, 25:1485-1489.
8. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999, 30:1434-1440.
9. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
10. Burroughs A., Hochhauser D., Meyer T. Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 2004, 5:409-418.
11. Davis C.R. Interventional radiological treatment of hepatocellular carcinoma. Cancer Control 2010, 17:87-99.
12. Peck-Radosavljevic M., Greten T.F., Lammer J., et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010, 22:391-398.
13. Fuss M., Salter B.J., Herman T.S., et al. External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image guided radiation therapy. Gastroenterology 2004, 127(Suppl 1):S206-S217.
14. Marrero J.A., Feng Z. Alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2010, 138:400-401.
15. Bruix J., Castells A., Bosch J., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996, 111:1018-1022.
16. Cormier J.N., Thomas K.T., Chari R.S., et al. Management of hepatocellular carcinoma. J Gastrointest Surg 2006, 10:761-780.
17. Geschwind J.H., Soulen M. Interventional Oncology-principles and practice 2008, Cambridge University Press, Cambridge, p. 146.
18. Delis S.G., Dervenis C. Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol 2008, 14:3452-3460.
19. Cabrera R., Nelson D.R. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2009, 31:461-476.
20. Llovet J.M., Di Bisceglie A.M., Bruix J., et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:698-711.
21. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19:329-338.
22. Pleguezuelo M., Germani G., Marelli L., et al. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008, 2:761-784.
23. Grieco A., Pompili M., Caminiti G., et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005, 54:411-418.
24. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005, 41:707-716.
25. Yamakado K., Nakatsuka A., Takaki H., et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008, 247:260-266.
26. Koda M., Murawaki Y., Mitsuda A., et al. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000, 88:529-537.
27. Tateishi R., Shiina S., Teratani T., et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1000 cases. Cancer 2005, 103:1201-1209.
28. Uflacker R, Cole S, Thomas M. Improved survival in hepatocellular carcinoma patients with low CLIP scores and liver-directed therapies: retrospective single institution study. Abstract P282, Presented at the 2010 CIRSE Annual Meeting and Postgraduate Course, Abstract book. Valencia, October 2-6, 2010. p. 405.
29. Shibata T., Isoda H., Hirokawa Y., et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?. Radiology 2009, 252:905-913.
30. Veltri A., Moretto P., Doriguzzi A., et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006, 16:661-669.
31. Zavaglia C., Corso R., Rampoldi A., et al. Is percutaneous radiofrequency thermal ablation of hepatocellular carcinoma a safe procedure?. Eur J Gastroenterol Hepatol 2008, 20:196-201.
32. Guglielmi A., Ruzzenente A., Valdegamberi A., et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg 2008, 12:192-198.
33. Vivarelli M., Guglielmi A., Ruzzenente A., et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004, 240:102-107.
34. Hiraoka A., Horiike N., Yamashita Y., et al. Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. Hepatogastroenterology 2008, 55:2171-2174.
35. Hasegawa S., Yamasaki N., Hiwaki T., et al. Factors that predict intrahepatic recurrence of hepatocellular carcinoma in 81 patients initially treated by percutaneous ethanol injection. Cancer 1999, 86:1682-1690.
36. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005, 129:122-130.
37. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004, 127:1714-1723.
38. Lencioni R.A., Allgaler H.P., Cloni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003, 228:235-240.
39. Cho Y.K., Kim J.K., Kim M.Y., et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009, 49:453-459.
40. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation versus percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009, 104:514-524.
41. McGahan J., Browning P.D., Brock J.M., et al. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990, 25:267-270.
42. Rossi S., Fornari F., Pathies C., et al. Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. Tumori 1990, 76:54-57.
43. Goldberg S.N., Gazelle G.S., Compton C.C., et al. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000, 88:2452-2463.
44. Kim S.K., Rhim H., Kim Y.S., et al. Radiofrequency thermal ablation of hepatic tumors: pitfalls and challenges. Abdom Imaging 2005, 30:727-733.
45. Lu D.S., Yu N.C., Raman S.S., et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005, 234:954-960.
46. Bhardwaj N., Strickland A.D., Ahmad F., et al. A comparative histological evaluation of the ablations produced by microwave, cryotherapy and radiofrequency in the liver. Pathology 2009, 41:168-172.
47. Livraghi T., Solbiati L., Meloni M., et al. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003, 226:441-445.
48. Lin S.M., Lin C.C., Chen W.T., et al. Radiofrequency ablation for hepatocellular carcinoma: a prospective comparison of four radiofrequency devices. J Vasc Interv Radiol 2007, 18:1118-1125.
49. Shibata T., Shibata T., Maetani Y., et al. Radiofrequency ablation for small hepatocellular carcinoma: prospective comparison of internally cooled electrode and expandable electrode. Radiology 2006, 238:346-353.
50. Tabuse K., Katsumi M., Kobayashi Y., et al. Microwave surgery: hepatectomy using a microwave tissue coagulator. World J Surg 1985, 9:135-143.
51. Tabuse K. A new operative procedure for hepatic surgery using a microwave tissue coagulator. Nippon Geka Hokan 1979, 48:160-172.
52. Goldburg N., Charboneau W.J., Dodd G.D., et al. Image-guided tumour ablation: proposal for standardization of terms and reporting criteria. Radiology 2003, 228:335-345.
53. Bhardwaj N., Strickland A.D., Ahmad F., et al. Liver ablation techniques: a review. Surg Endosc 2010, 24:254-265.
54. Shibata T., Iimuro Y., Yamamoto Y., et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 2002, 223:331-337.
55. Dong B., Liang P., Yu X., et al. Percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma: results in 234 patients. AJR Am J Roentgenol 2003, 180:1547-1555.
56. Liang P., Dong B., Yu X., et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology 2005, 235:299-307.
57. Arnott J. Practical illustrations of the remedial efficacy of a very low or anesthetic temperature in cancer. Lancet 1850, 2:257-259.
58. Mazur P., Rall W.F., Leibo S.P. Kinetics of water loss and the likelihood of intracellular freezing in mouse ova (influence of the method of calculating the temperature dependence of water permeability). Cell Biophys 1984, 6:197-213.
59. Bryant G. DSC measurement of cell suspensions during successive freezing runs: implications for the mechanisms of intracellular ice formation. Cryobiology 1995, 32:114-128.
60. Callstrom M.R., Charboneau J.W. Technologies for ablation of hepatocellular carcinoma. Gastroenterology 2008, 134:1831-1835.
61. Orlacchio A., Bazzocchi G., Pastorelli D., et al. Percutaneous cryoablation of small hepatocellular carcinoma with US guidance and CT monitoring: initial experience. Cardiovasc Intervent Radiol 2008, 31:587-594.
62. Shimizu T., Sakuhara Y., Abo D., et al. Outcome of MR-guided percutaneous cryoablation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2009, 16:816-823.
63. Morrison P.R., Silverman S.G., Tuncali K., et al. MRI-guided cryotherapy. J Magn Reson Imaging 2008, 27:410-412.
64. Gilbert J.C., Onik G.M., Hoddick W.K., et al. Real time ultrasonic monitoring of hepatic cryosurgery. Cryobiology 1985, 22:319-330.
65. Seifert J.K., Morris D.L. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1999, 23:109-113.
66. Pearson A.S., Izzo F., Fleming R.Y., et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg 1999, 178:592-599.
67. Nikfarjam M., Vijayaragavan M., Malcontenti-Wilson C., et al. Progressive microvascular injury in liver and colorectal liver metastases following laser induced focal hyperthermia therapy. Lasers Surg Med 2005, 37:64-67.
68. Pacella C.M., Bizzarri G., Francica G., et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with a tumor size of 4.0 cm or smaller: analysis of factors affecting the achievement of tumor necrosis. J Vasc Interv Radiol 2005, 16:1447-1457.
69. Vogl T.J., Straub R., Eichler K., et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: experience with complications in 899 patients (2520 lesions). Radiology 2002, 225:367-377.
70. Pacella C.M., Bizzarri G., Magnolfi F., et al. Laser thermal ablation in the treatment of small hepatocellular carcinoma: results in 74 patients. Radiology 2001, 221:712-720.
71. Vogl T.J., Straub R., Zangos S., et al. MR-guided laser-induced thermotherapy (LITT) of liver tumours: experimental and clinical data. Int J Hyperthermia 2004, 20:713-724.
72. Stroszczynski C., Gaffke G., Gnauck M., et al. Current concepts and recent developments of laser ablation in tumor therapy. Radiologe 2004, 44:320-329.
73. Curley S.A., Izzo F., Ellis L.M., et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000, 232:381-391.
74. Barnett C.C., Curley S.A. Ablative techniques for hepatocellular carcinoma. Semin Oncol 2001, 28:487-496.
75. Caspani B., Ierardi A.M., Motta F., et al. Small nodular hepatocellular carcinoma treated by laser thermal ablation in high risk locations: preliminary results. Eur Radiol 2010, 20:2286-2292.
76. Germer C.T., Roggan A., Ritz J.P., et al. Optical properties of native and coagulated human liver tissue and liver metastases in the near infrared range. Lasers Surg Med 1998, 23:194-203.
77. Orlowski S., Mir L.M. Cell electropermeabilization: a new tool for biochemical and pharmacological studies. Biochim Biophys Acta 1993, 1154:51-63.
78. Rubinsky B., Onik G., Mikus P. Irreversible electroporation: a new ablation modality: clinical implications. Technol Cancer Res Treat 2007, 6:37-48.
79. Al-Sakere B., André F., Bernat C., et al. Tumor ablation with irreversible electroporation. PLoS One 2007, 2:e1135.
80. Guo Y., Zhang Y., Klein R., et al. Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res 2010, 70:1555-1563.
81. Ball C., Thomson K.R., Kavnoudias H. Irreversible electroporation: a new challenge in "out of operating theater" anesthesia. Anesth Analg 2010, 110:1305-1309.
82. Kennedy J.E. High-intensity focused ultrasound in the treatment of solid tumors. Nat Rev Cancer 2005, 5:321-327.
83. Hill C.R., Rivens I., Vaughan M., et al. Lesion development in focused ultrasound surgery: a general model. Ultrasound Med Biol 1994, 20:259-269.
84. Vaughan M., Haar G., Hill C.R., et al. Minimally invasive cancer surgery using focused ultrasound: a pre-clinical, normal tissue study. Br J Radiol 1994, 67:267-274.
85. Wu F., Chen W.Z., Bai J., et al. Pathological changes in human malignant carcinoma treated with high-intensity focused ultrasound. Ultrasound Med Biol 2001, 27:1099-1106.
86. Zhang L., Zhu H., Jin C., et al. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol 2009, 19:437-444.
87. Li Y., Sha W., Zhou Y., et al. Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22:2148-2154.
88. Chou F.I., Fang K.C., Chung C., et al. Lipiodol uptake and retention by human hepatoma cells. Nucl Med Biol 1995, 22:379-386.
89. Kan Z., McCuskey P.A., Wright K.C., et al. Role of Kupffer cells in iodized oil embolization. Invest Radiol 1994, 29:990-993.
90. Sasaki Y., Imaoka S., Kasugai H., et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987, 60:1194-1203.
91. Ohishi H., Uchida H., Yoshimura H., et al. Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology 1985, 154:25-29.
92. Solomon B., Soulen M.C., Baum R.A., et al. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999, 10:793-798.
93. Varela M., Real M.I., Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007, 46:474-481.
94. Xiao E.H., Guo D., Bian D.J. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells. World J Gastroenterol 2009, 15:4582-4586.
95. Brown D.B., Cardella J.F., Sacks D., et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009, 20(Suppl):S219-S226.
96. Kim W., Clark T.W., Baum R.A., et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001, 12:965-968.
97. Llovet J.M., Real M.I., Montaña X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
98. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35:1164-1171.
99. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
100. Cammà C., Schepis F., Orlando A., et al. Transarterial chemoembolization or unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002, 224:47-54.
101. Mabed M., Esmaeel M., El-Khodary T., et al. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 2009, 18:492-499.
102. Lammer J., Malagari K., Vogl T., et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010, 33:41-52.
103. Malagari K., Pomoni M., Kelekis A., et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with Bead-Block for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010, 33:541-551.
104. Salem R., Lewandowski R.J., Atassi B., et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (Thera Sphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005, 16:1627-1639.
105. Riaz A., Lewandowski R., Kulik L. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009, 20:1121-1130.
106. Salem R., Lewandowski R., Roberts C., et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004, 15:335-345.
107. Salem R., Lewandowski R.J., Mulcahy M.F., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138:52-64.
108. Kooby D.A., Egnatashvili V., Srinivasan S., et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010, 21:224-230.
109. Alexander H.R., Butler C.C. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010, 2:132-141.
110. Miao N., Pingpank J.F., Alexander H.R., et al. Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008, 3:815-823.
111. Alexander H.R., Libutti S.K., Pingpank J.F., et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 2005, 12:138-144.
112. Yamakado K., Nakatsuka A., Ohmori S., et al. Radiofrequency ablation combined with chemoembolization in hepatocellular carcinoma: treatment response based on tumor size and morphology. J Vasc Interv Radiol 2002, 13:1225-1232.
113. Tateishi R., Shiina S., Ohki T., et al. Treatment strategy for hepatocellular carcinoma: expanding the indications for radiofrequency ablation. J Gastroenterol 2009, 44(Suppl 19):142-146.
114. Lencioni R., Crocetti L., Petruzzi P., et al. Doxorubicin-eluting bead enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008, 49:217-222.
115. Ahmed M., Liu Z., Lukyanov A.N., et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005, 235:469-477.
116. Kadivar F., Soulen M.C. Enhancing ablation: synergies with regional and systemic therapies. J Vasc Interv Radiol 2010, 21:S251-S256.
117. Gasparini D., Sponza M., Marzio A., et al. Combined treatment, TACE and RF ablation, in HCC: preliminary results. Radiol Med 2002, 104:412-420.
118. Liao G.S., Yu C.Y., Shih M.L., et al. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. Eur J Surg Oncol 2008, 34:61-66.